Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
-
Scryb Launches New AI Governance Technology Business Unit, 'Raidian'
-
Global Times: People's Daily article says favorable conditions for China's economic development remain unchanged
-
Storyinstanavigation Ranks the Top 5 Best Instagram Story Viewers Online
-
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
-
CWTI Provides Revised Update on Canada Postal Strike Delay Mailing of the Company's 2024 Annual General Meeting Materials
-
Studies Highlight Progress in Preventing and Treating Blood Cancers and Pre-Cancerous Conditions
-
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leuke
-
Siemon Releases 2024 ESG Report: A Commitment to Sustainability
-
Notice of Convening Hearing
-
Max Stock Limited: Immediate report of changes to interested party holdings
-
National Press Club: Family Of Austin Tice Available for Interviews at St. John's Church
-
Remarkable Determination: A Contestant Submitted 200 Entries, Yet None Reached The Longlist
-
Renovate.com Bridges Home Improvement Gap by Prequalifying Financing and Connecting Homeowners With Contractors
-
XMX LONDON LIMITED Celebrates 20 Years of Excellence in High End Residential Construction and Commercial Building Development
-
Nanning: A Colorful City of Cultural Diversity
-
Monster Energy's David Wise Claims Third Place in Men's Freeski Halfipe at the FIS World Cup at China's Secret Garden
-
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
-
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
-
FinCEN and DOJ Appeal Corporate Transparency Act Nationwide Injunction Two Days After Texas Ruling on BOIR
-
Vision Marine and Armada Partner to Produce an Innovative Electric Pontoon for North America’s Regulated Lakes
-
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
-
RBB Law Group Partners with Amazon to Transform Car Buying and Ensure Fair Rebates Nationwide
-
EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
-
DKbitex to Launch DKBC: A Revolutionary New Cryptocurrency
-
Hosted.com Launches AI-Powered Domain Name Generator, Simplifying The Domain Registration Process
-
Staking AI Redefines Crypto Investments: Discover the Highest APY Platform of 2024
-
ZeusX Celebrates Milestones in Connecting Gamers Through a Secure Marketplace
-
PRIME MINISTER OF MONGOLIA MAKES HISTORIC VISIT TO MIDDLE EAST
-
Icona Capital Acquires Island In Maldives for an Ultra-Luxury Project
-
Global Times: Clay Figure Zhang's works naturally reflect spiritual state of the times
-
DKbitex to Launch DKDC: A Revolutionary New Cryptocurrency
-
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
-
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
-
Orca Bio Presents Clinical Results on Use of Orca-Q® without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
-
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
-
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
-
Twenty-three Years Running for the Kids of St. Jude: St. Jude Memphis Marathon Weekend Reaches Fundraising Record
-
Caribbean Airlines Brings the Region Closer with New Service to Guadeloupe
-
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
-
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
-
Pennsylvania Skill, powered by Pace-O-Matic, Responds to Commonwealth Court Ruling in Favor of Skill Games
-
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
-
HII Christens Virginia-Class Attack Submarine Arkansas (SSN 800)
-
United Flow Technologies Acquires The TDH Company to Enhance Water and Wastewater Treatment Solutions
